Senator Warren Urges FTC to Probe Novo Nordisk-Catalent Merger

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, according to a letter sent to FTC Chair Lina Khan.

• Warren says the merger could lead to higher costs for prescription drugs and asks the FTC to block the deal if it is found to be breaking antitrust law
• NOTE: Novo Seals $11 Billion Catalent Deal to Lift Wegovy Output

To contact the reporter on this story:
Maria Luiza Rabello in Washington at mrabello@bloomberg.net

To contact the editors responsible for this story:
Megan ...